Quantify

Beam Therapeutics Inc. vs Pfizer, Inc. — Stock Comparison

Beam Therapeutics Inc. (BEAM) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.

vs
Q·Score Winner
Pfizer, Inc.
PFE6.4/10vs 6/10

Pfizer, Inc. narrowly edges Beam Therapeutics Inc. on Q·Score (6.4 vs 6 out of 10), led by Quality (6.4 vs 1.2) and Valuation (7.7 vs 5.7). Beam Therapeutics Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for BEAM (+49.6%) than for PFE (+15.8%).

Price Performance

Normalised to 100 at period start — shows relative performance.

Loading…
● BEAM● PFE

Q·Score Breakdown

6
Neutral
Overall
6.4
Neutral
1.2
Quality
6.4
9.2
Health
7
7.7
Growth
5.1
5.7
Valuation
7.7
8
Sentiment
5.3
BEAM

Clean balance sheet with low leverage (0.2× debt-to-equity).

⚠ currently unprofitable (-40% margin).

PFE

Forward P/E of 8.9× is low relative to sector peers.

⚠ earnings contracting 10% year-over-year.

Analyst Consensus

Bullish
+49.6%
Target $51.07
15 analysts
Neutral
+15.8%
Target $29.19
27 analysts

Fundamentals

BEAM
PFE
—
Trailing P/E
19.2×
-7.2×
Forward P/E
8.9×
-40.23%
Profit Margin
11.83%
-146.90%
Gross Margin
74.80%
-5.77%
ROE
8.31%
324.90%
Revenue Growth
5.40%
—
Earnings Growth
-10.10%
2.20
Beta
0.29
—
Dividend Yield
6.61%
$3.5B
Market Cap
$143.7B
52-Week Range
BEAM
$1689% of range$36
PFE
$2337% of range$29

Frequently Asked Questions

BEAM vs PFE: which stock scores better overall?

Based on Q·Score, Pfizer, Inc. (PFE) scores 6.4/10 versus Beam Therapeutics Inc. (BEAM) at 6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.

Which has better revenue growth: BEAM or PFE?

Beam Therapeutics Inc. (BEAM) scores higher on Growth (7.7/10 vs 5.1/10). Beam Therapeutics Inc. reports revenue growth (324.9% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Is BEAM or PFE more attractively valued?

Pfizer, Inc. (PFE) scores higher on Valuation (7.7/10 vs 5.7/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

What do analysts say about BEAM vs PFE?

There are 15 analysts covering BEAM with a consensus price target of $51.07, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Which is more profitable: BEAM or PFE?

Pfizer, Inc. (PFE) scores higher on Quality (6.4/10 vs 1.2/10). Net profit margin: BEAM at -40.2%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Which has stronger financial health: BEAM or PFE?

Beam Therapeutics Inc. (BEAM) scores higher on Financial Health (9.2/10 vs 7/10). Market beta: BEAM at 2.20, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

What are the market caps of BEAM and PFE?

Beam Therapeutics Inc. (BEAM) has a market capitalisation of $3.5B, while Pfizer, Inc. (PFE) has a market cap of $143.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Do BEAM or PFE pay dividends?

BEAM does not currently pay a dividend, while PFE pays a dividend yield of 6.61%. Dividend yields fluctuate with share price and company payout decisions.

Related Comparisons

JNJ vs PFEMRNA vs PFELLY vs PFE

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →

Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026